DrugDev and Informa partner to enable easy site identification for clinical trials

10th May 2017 (Last Updated May 10th, 2017 18:30)

DrugDev and Informa’s Pharma Intelligence vertical, Citeline, have integrated their respective platforms to allow easy and efficient identification of ideal sites for conducting clinical trials.

DrugDev and Informa’s Pharma Intelligence vertical, Citeline, have integrated their respective platforms to allow easy and efficient identification of ideal sites for conducting clinical trials.

Citeline’sTrialtrove and Sitetrove intelligence platforms are integrated with DrugDev’s unified clinical operations suite DrugDev Spark.

The information on study planning and site identification available through DrugDev Spark will be extended with the incorporation of indexing information captured by Citeline to the universal site identifier called DrugDev Golden Number.

The indexing information is related to more than 390,000 investigators in more than 265,000 trials being conducted in more than 170 countries.

The incorporation of data will allow the firms’ mutual clients to easily identify the required clinical sites.

DrugDev Spark users can also efficiently move from study planning and site identification to other solutions such as site activation, site payments, eConsent, learning management, document exchange and site engagement.

"Our customers need data, together with technology, to deliver new and innovative drugs into the pharmaceutical market."

Informa Pharma Intelligence president Linda Blackerby said: “We are excited to be working with DrugDev for our mutual clients’ benefit in improving the speed and success of clinical drug development.

“Our customers need data, together with technology, to deliver new and innovative drugs into the pharmaceutical market.”

The firm's mutual clients are subscribing to both Trialtrove and Sitetrove systems through an XML feed and will also have access to multiple data sources.

DrugDev Data Solutions president Elisa Cascade said: “By integrating data in one trusted location, we can now simplify the evidence-based planning and site identification process for our customers through access to a single integrated view of data from all available sources, enabling sponsors to make better site selection decisions, faster.”

The combination of data assets is expected to allow consideration of all information in a single query, therefore resulting in faster and better decision-making, contrary to the existing method of running queries in different systems and later consolidating them for understanding the study.